Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia

Abstract

Three members of the angiopoietin-like (ANGPTL) protein family-ANGPTL3, ANGPTL4 and ANGPTL8- are important regulators of plasma lipoproteins. They inhibit the enzyme lipoprotein lipase, which plays a key role in the intravascular lipolysis of triglycerides present in some lipoprotein classes. This review focuses on the role of ANGPTL3 as emerged from the study of genetic variants of Angptl3 gene in mice and humans. Both loss of function genetic variants and inactivation of Angptl3 gene in mice are associated with a marked reduction of plasma levels of triglyceride and cholesterol and an increased activity of lipoprotein lipase and endothelial lipase. In humans with ANGPTL3 deficiency, caused by homozygous loss of function (LOF) variants of Angptl3 gene, the levels of all plasma lipoproteins are greatly reduced. This plasma lipid disorder referred to as familial combined hypolipidemia (FHBL2) does not appear to be associated with distinct pathological manifestations. Heterozygous carriers of LOF variants have reduced plasma levels of total cholesterol and triglycerides and are at lower risk of developing atherosclerotic cardiovascular disease, as compared to non-carriers. These observations have paved the way to the development of strategies to reduce the plasma level of atherogenic lipoproteins in man by the inactivation of ANGPTL3, using either a specific monoclonal antibody or anti-sense oligonucleotides.

Keywords

angiopoietin-like protein 3 / ANGPTL3 deficiency / loss of function variants / FHBL2

References

[1] Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism[J]. Trends Cardiovasc Med, 2008, 18(1): 6–14

[2] Santulli G. Angiopoietin-like proteins: a comprehensive look[J]. Front Endocrinol (Lausanne), 2014, 5: 4

[3] Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins[J]. Biochim Biophys Acta, 2012, 1821(5): 782–789.

[4] Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking[J]. Open Biol, 2016, 6(4): 150272

[5] Kersten S. Physiological regulation of lipoprotein lipase[J]. Biochim Biophys Acta, 2014, 1841(7): 919–933.

[6] Dijk W, Kersten S. Regulation of lipid metabolism by angiopoietin-like proteins[J]. Curr Opin Lipidol, 2016, 27(3): 249–256

[7] Koishi R, Ando Y, Ono M, Angptl3 regulates lipid metabolism in mice[J]. Nat Genet, 2002, 30(2): 151–157

[8] Shimizugawa T, Ono M, Shimamura M, ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase[J]. J Biol Chem, 2002, 277(37): 33742–33748

[9] Fujimoto K, Koishi R, Shimizugawa T, Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity[J]. Exp Anim, 2006, 55(1): 27–34

[10] Köster A, Chao YB, Mosior M, Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism[J]. Endocrinology, 2005, 146(11): 4943–4950

[11] Musunuru K, Pirruccello JP, Do R, Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia[J]. N Engl J Med, 2010, 363(23): 2220–2227

[12] Minicocci I, Montali A, Robciuc MR, Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization[J]. J Clin Endocrinol Metab, 2012, 97(7): E1266–E1275

[13] Robciuc MR, Maranghi M, Lahikainen A, Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids[J]. Arterioscler Thromb Vasc Biol, 2013, 33(7): 1706–1713

[14] Pisciotta L, Favari E, Magnolo L, Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3[J]. Circ Cardiovasc Genet, 2012, 5(1): 42–50

[15] Martín-Campos JM, Roig R, Mayoral C, Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation[J]. Clin Chim Acta, 2012, 413(5-6): 552–555

[16] Noto D, Cefalù AB, Valenti V, Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia[J]. Arterioscler Thromb Vasc Biol, 2012, 32(3): 805–809

[17] Minicocci I, Santini S, Cantisani V, Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis[J]. J Lipid Res, 2013, 54(12): 3481–3490

[18] Perk J, De Backer G, Gohlke H, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)[J]. Eur Heart J, 2012, 33(13): 1635–1701

[19] Minicocci I, Cantisani V, Poggiogalle E, Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis[J]. Int J Cardiol, 2013, 168(4): 4375–4378

[20] Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum[J]. Adv Clin Chem, 2011, 54: 81–107

[21] Di Costanzo A, Di Leo E, Noto D, Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia[J]. J Clin Lipidol, 2017, 11(5): 1234–1242

[22] Kathiresan S, Melander O, Guiducci C, Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans[J]. Nat Genet, 2008, 40(2): 189–197

[23] Teslovich TM, Musunuru K, Smith AV, Biological, clinical and population relevance of 95 loci for blood lipids[J]. Nature, 2010, 466(7307): 707–713

[24] Romeo S, Yin W, Kozlitina J, Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans[J]. J Clin Invest, 2009, 119(1): 70–79

[25] Dewey FE, Gusarova V, Dunbar RL, Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease[J]. N Engl J Med, 2017, 377(3): 211–221

[26] Stitziel NO, Khera AV, Wang X, . ANGPTL3 deficiency and protection against coronary artery disease[J]. J Am Coll Cardiol, 2017, 69(16): 2054–2063

[27] Ono M, Shimizugawa T, Shimamura M, Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo[J]. J Biol Chem, 2003, 278(43): 41804–41809

[28] Quagliarini F, Wang Y, Kozlitina J, Atypical angiopoietin-like protein that regulates ANGPTL3[J]. Proc Natl Acad Sci U S A, 2012, 109(48): 19751–19756

[29] Haller JF, Mintah IJ, Shihanian LM, ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[J]. J Lipid Res, 2017, 58(6): 1166–1173

[30] Peloso GM, Auer PL, Bis JC, Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks[J]. Am J Hum Genet, 2014, 94(2): 223–232

[31] Chi X, Britt EC, Shows HW, ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase[J]. Mol Metab, 2017, 6(10): 1137–1149

[32] Shan L, Yu XC, Liu Z, The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms[J]. J Biol Chem, 2009, 284(3): 1419–1424

[33] Liu J, Afroza H, Rader DJ, Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases[J]. J Biol Chem, 2010, 285(36): 27561–27570

[34] Shimamura M, Matsuda M, Yasumo H, Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase[J]. Arterioscler Thromb Vasc Biol, 2007, 27(2): 366–372

[35] Gusarova V, Alexa CA, Wang Y, ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys[J]. J Lipid Res, 2015, 56(7): 1308–1317

[36] Shimamura M, Matsuda M, Ando Y, Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor[J]. Biochem Biophys Res Commun, 2004, 322(3): 1080–1085

[37] Inukai K, Nakashima Y, Watanabe M, ANGPTL3 is increased in both insulin-deficient and-resistant diabetic states[J]. Biochem Biophys Res Commun, 2004, 317(4): 1075–1079

[38] Nidhina Haridas PA, Soronen J, Sädevirta S, Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin[J]. J Clin Endocrinol Metab, 2015, 100(10): E1299–E1307

[39] Muniyappa R, Abel BS, Asthana A, Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy[J]. J Clin Lipidol, 2017, 11(2): 543–550

[40] Moon HS, Dalamaga M, Kim SY, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals[J]. Endocr Rev, 2013, 34(3): 377–412

[41] Ito M, Takamatsu J, Matsuo T, Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement[J]. Clin Endocrinol (Oxf), 2003, 58(5): 621–626

[42] Johansson L, Rudling M, Scanlan TS, Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice[J]. Proc Natl Acad Sci U S A, 2005, 102(29): 10297–10302

[43] Fugier C, Tousaint JJ, Prieur X, The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone[J]. J Biol Chem, 2006, 281(17): 11553–11559

[44] Joseph SB, Laffitte BA, Patel PH, Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors[J]. J Biol Chem, 2002, 277(13): 11019–11025

[45] Inaba T, Matsuda M, Shimamura M, Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor[J]. J Biol Chem, 2003, 278(24): 21344–21351

[46] Kaplan R, Zhang T, Hernandez M, Regulation of the angiopoietin-like protein 3 gene by LXR[J]. J Lipid Res, 2003, 44(1): 136–143

[47] Khovidhunkit W, Kim MS, Memon RA, Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host[J]. J Lipid Res, 2004, 45(7): 1169–1196

[48] Lu B, Moser A, Shigenaga JK, The acute phase response stimulates the expression of angiopoietin like protein 4[J]. Biochem Biophys Res Commun, 2010, 391(4): 1737–1741

[49] Minicocci I, Tikka A, Poggiogalle E, Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism[J]. J Lipid Res, 2016, 57(6): 1097–1107

[50] Wang Y, Gusarova V, Banfi S, Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion[J]. J Lipid Res, 2015, 56(7): 1296–1307

[51] Ando Y, Shimizugawa T, Takeshita S, A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice[J]. J Lipid Res, 2003, 44(6): 1216–1223

[52] Xu YX, Redon V, Yu H, Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol[J]. Atherosclerosis, 2018, 268: 196– 206

[53] Stejskal D, Karpísek M, Humenanská V, Angiopoietin-like protein 3: development, analytical characterization, and clinical testing of a new ELISA[J]. Gen Physiol Biophys, 2007, 26(3): 230–233

[54] Robciuc MR, Tahvanainen E, Jauhiainen M, Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample[J]. J Lipid Res, 2010, 51(4): 824–831

[55] Hatsuda S, Shoji T, Shinohara K, Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects[J]. J Vasc Res, 2007, 44(1): 61–66

[56] Mehta N, Qamar A, Qu L, Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5): 1057–1063

[57] Fazio S, Minnier J, Shapiro MD, Threshold effects of circulating angiopoietin-like 3 levels on plasma lipoproteins [J]. J Clin Endocrinol Metab, 2017, 102(9): 3340–3348

[58] Gaudet D, Gipe DA, Pordy R, ANGPTL3 inhibition in homozygous familial hypercholesterolemia[J]. N Engl J Med, 2017, 377(3): 296–297

[59] Graham MJ, Lee RG, Brandt TA, Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides [J]. N Engl J Med, 2017, 377(3): 222–232

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.